



**Supplementary Fig. 4.** Changes from 12-month values in key clinical parameters for the different regimens during the 24 months of the study. Values are presented as mean  $\pm$  standard error. Regimens used after 12 months: (A) glycosylated hemoglobin (HbA1c), (B) body weight, (C) body mass index (BMI), (D) estimated glomerular filtration rate by Chronic Kidney Disease Epidemiology Collaboration equation (eGFR-CKD-EPI), (E) alanine transaminase (ALT), and (F) total cholesterol. MTF+EMPA, metformin with empagliflozin; MTF+SITA, metformin with sitagliptin; Triple, continuing metformin, sitagliptin, and empagliflozin. <sup>a</sup> $P < 0.05$  vs. the extent of changes between the groups (analysis of variance [ANOVA] and *post hoc* Duncan test).